Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors
Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors
复制标题
DOI：
10.1093/cid/ciaa849
复制
发表时间：
2021-01-15
影响因子：
11.8
通讯作者：
Ullum, Henrik
中科院分区：
文献类型：
--
作者：
Erikstrup, Christian;Hother, Christoffer Egeberg;Ullum, Henrik
背景。严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 引起的大流行对我们的社会造成了巨大影响。需要了解 SARS-CoV-2 的血清流行情况才能准确监测流行病的传播并计算感染死亡率 (IFR)。这些措施可能有助于当局做出明智的决定并调整当前的社会干预措施。目的是在全国范围内的献血者中进行实时血清流行率调查，作为估计既往 SARS-CoV-2 感染情况和基于人群的 IFR 的工具。使用商业侧流检测对 4 月 6 日至 5 月 3 日期间献血的 17-69 岁丹麦献血者进行了 SARS-CoV-2 免疫球蛋白 M 和 G 抗体检测。比较地理区域之间的抗体状态，并计算 IFR 的估计值。在报告 95% 置信区间 (CI) 时，考虑到测试验证的不确定性，对血清阳性率进行了调整，以检测灵敏度和特异性。结果。对首批 20 640 名献血者进行了检测，计算出综合调整血清阳性率为 1.9%（95% CI，0.8-2.3）。不同地区的血清流行率有所不同。利用有关死亡人数和人口数量的现有数据，对患者进行综合 IFR
Background. The pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has tremendous consequences for our societies. Knowledge of the seroprevalence of SARS-CoV-2 is needed to accurately monitor the spread of the epidemic and to calculate the infection fatality rate (IFR). These measures may help the authorities make informed decisions and adjust the current societal interventions. The objective was to perform nationwide real-time seroprevalence surveying among blood donors as a tool to estimate previous SARS-CoV-2 infections and the population-based IFR.Methods. Danish blood donors aged 17-69 years giving blood 6 April to 3 May were tested for SARS-CoV-2 immunoglobulin M and G antibodies using a commercial lateral flow test. Antibody status was compared between geographical areas, and an estimate of the IFR was calculated. Seroprevalence was adjusted for assay sensitivity and specificity taking the uncertainties of the test validation into account when reporting the 95% confidence intervals (CIs).Results. The first 20 640 blood donors were tested, and a combined adjusted seroprevalence of 1.9% (95% CI, .8-2.3) was calculated. The seroprevalence differed across areas. Using available data on fatalities and population numbers, a combined IFR in patients